Stuart Peltz
CEO & Founder
Former CEO of PTC BioTech for 27 yrs. RWJ Professor - Department of Molecular Genetics & Microbiology
Turning Biotech IP into a repeatable, AI-driven advantage.
LexiQure combines BioTech drug development & Patent Law know-how with AI powered large-scale patent analysis, to generate De Novo patents opportunities.
Why LexiQure exists
Biotech innovation is too slow and expensive, not leveraging existing past work. LexiQure bridges the gap by giving R&D, legal, and business teams a single AI layer to search prior art, understand value disparities, and generate defensible, high-quality claims.
Our platform ingests global biotech patent data, scientific literature, and internal know-how, then organizes it into a vector database optimized for retrieval-augmented generation. On top of that, we add domain-specific guardrails so that every suggestion is grounded in real IP context and aligned with your strategy.
Biotech patents & prior art
Vector search & RAG
Human-in-the-loop review
De-novo IP creation
LexiQure in numbers
10k+
biotech-focused patents analyzed across modalities, indications, and claim structures to train
the LexiQure IP engine.
LexiQure Workflows
Team
LexiQure is built by operators who sit at the intersection of biotech, AI research, and patent law. Meet the founding team behind the platform.
Mitchell Wong
Chief Legal Officer
Mitch has been an IP Patent lawyer in biotech for for 16 yrs at Ashmasons LLP
Benjamin Maisano
Technology Advisor
A healthcare technology leader for 21 yrs as CTO at Mt. Sinai & Atlantic Health, Tendo, and two startups